CAGRILINTIDE - 17 ads

Friday, August 29, 2025

Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. It is mainly used for the treatment of type 2 diabetes. It can lower blood sugar and control blood sugar levels...

Friday, August 22, 2025

Cagrilintide is a novel long-acting acylated glucagon analogue under investigation as a non-selective agonist of the amygdalin receptor (AMYR) and calcitonin G-protein-coupled receptor (CChemicalbookTR).Cagrilintide significantly reduces body weight and decreases food intake.Cagrilintide...

Wednesday, August 20, 2025

Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. It is mainly used for the treatment of type 2 diabetes. It can lower blood sugar and control blood sugar levels...

Friday, August 01, 2025

Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. It is mainly used for the treatment of type 2 diabetes. It can lower blood sugar and control blood sugar levels...

Friday, July 25, 2025

Cagrilintide is a novel long-acting acylated glucagon analogue under investigation as a non-selective agonist of the amygdalin receptor (AMYR) and calcitonin G-protein-coupled receptor (CChemicalbookTR).Cagrilintide significantly reduces body weight and decreases food intake.Cagrilintide...

Saturday, July 19, 2025

Cagrilintide is a novel long-acting acylated glucagon analogue under investigation as a non-selective agonist of the amygdalin receptor (AMYR) and calcitonin G-protein-coupled receptor (CChemicalbookTR).Cagrilintide significantly reduces body weight and decreases food intake.Cagrilintide...

Thursday, July 17, 2025

Cagrilintide is a novel long-acting acylated glucagon analogue under investigation as a non-selective agonist of the amygdalin receptor (AMYR) and calcitonin G-protein-coupled receptor (CChemicalbookTR).Cagrilintide significantly reduces body weight and decreases food intake.Cagrilintide...

Friday, July 11, 2025

Cagrilintide 是一种新型长效酰化胰高血糖素类似物，作为苦杏仁苷受体 （AMYR） 和降钙素 G 蛋白偶联受体 （CChemicalbookTR） 的非选择性激动剂，正在研究中。Cagrilintide 可显著降低体重并减少食物摄入量。Cagrilintide 具有用于肥胖研究的潜力。 品牌： Soarwin CAS号：1415456-99-3 EINECS编号：206-141-6 Location : 重庆渝北, 401000 渝北, Contact : meng meng, +18 7 23 93 07 08

Wednesday, July 09, 2025

Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. It is mainly used for the treatment of type 2 diabetes. It can lower blood sugar and control blood sugar levels...

Friday, July 04, 2025

Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. It is mainly used for the treatment of type 2 diabetes. It can lower blood sugar and control blood sugar levels...

Tuesday, July 01, 2025

Cagrilintide is a novel long-acting acylated glucagon analogue under investigation as a non-selective agonist of the amygdalin receptor (AMYR) and calcitonin G-protein-coupled receptor (CChemicalbookTR).Cagrilintide significantly reduces body weight and decreases food intake.Cagrilintide...

Wednesday, June 25, 2025

Cagrilintide is a novel long-acting acylated glucagon analogue under investigation as a non-selective agonist of the amygdalin receptor (AMYR) and calcitonin G-protein-coupled receptor (CChemicalbookTR).Cagrilintide significantly reduces body weight and decreases food intake.Cagrilintide...

Wednesday, June 25, 2025

Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. It is mainly used for the treatment of type 2 diabetes. It can lower blood sugar and control blood sugar levels...

Tuesday, June 24, 2025

Cagrilintide is a novel long-acting acylated glucagon analogue under investigation as a non-selective agonist of the amygdalin receptor (AMYR) and calcitonin G-protein-coupled receptor (CChemicalbookTR).Cagrilintide significantly reduces body weight and decreases food intake.Cagrilintide...

Friday, April 25, 2025

Quantity : 9999 - Price : 1,00 €

Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. It is mainly used for the treatment of type 2 diabetes. It can lower blood sugar and control blood sugar levels...

Tuesday, April 22, 2025

Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. It is mainly used for the treatment of type 2 diabetes. It can lower blood sugar and control blood sugar levels...

Wednesday, April 16, 2025

Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. It is mainly used for the treatment of type 2 diabetes. It can lower blood sugar and control blood sugar levels...